1. Introduction {#s0005}
===============

Post-traumatic stress disorder (PTSD) is an anxiety disorder occurring in response to traumatic stress such as may occur in combat. A retrospective study of t veterans with PTSD showed a two-fold higher risk of developing dementia compared to veterans without PTSD even after adjusting for other comorbidities ([@bb0405]), and PTSD increases the risk for dementia and Alzheimer\'s disease (AD) ([@bb0065]; [@bb0085]; [@bb0380]; [@bb0405]b). Traumatic brain injury (TBI) is one of the leading causes of death and disability in the young population ([@bb0085]). Survivors of TBI often suffer from permanent neurological and cognitive deficits, with increased risk for developing AD. There is considerable comorbidity of PTSD with TBI, especially among war veterans ([@bb0010]; [@bb0015]), which raises the question of whether the two conditions interact regarding the risk of neurodegenerative changes and dementia.

The most common form of dementia is AD, which is characterized by brain pathology consisting of extracellular Aβ plaques, intraneuronal tangles of phosphorylated tau protein, synapse loss, and neuronal loss ([@bb0115]; [@bb0190]).The transition from mild cognitive impairment (MCI) to AD can be monitored in PET studies with amyloid-beta (Aβ) ligands such as \[^11^C\]-PiB and \[^18^F\]-AV45 (Florbetapir) ([@bb0280]; [@bb0325]). Increased Aβ plaque deposition has been reported in post mortem examination of brain from TBI victims ([@bb0170]), and is now being documented in PET studies of TBI patients. For example, in a \[^11^C\]-PiB PET study of TBI patients, researchers found increased Aβ deposition in the posterior cingulate cortex, cerebellum and striatum ([@bb0335]), regions that extensively overlapped with the pattern of Aβ deposition found in AD brain. Indeed, Aβ plaques have been observed in about one third of TBI subjects ([@bb0170], [@bb0165]), irrespective of patient\'s age, suggesting that TBI is a causative factor in Aβ deposition ([@bb0370]). Interestingly, Aβ plaques were seen shortly after an injury event ([@bb0135]) but not in long term survivors of TBI ([@bb0050]), suggesting that enhanced amyloid clearance mechanisms may compensate for an acute injury-related accumulation.

There is scant documentation of the relationship between PTSD with amyloid deposition. Studies in rodent models of PTSD due to chronic stress indicated accelerated amyloid plaque formation and Aβ release ([@bb0310]). To investigate this phenomenon, the Department of Defense (DOD) funded a component of the Alzheimer\'s Disease Neuroimaging Initiative (ADNI) specifically to investigate amyloid burden, cognitive changes, and brain structural/functional changes in Vietnam War veterans. A preliminary analysis of data from the DOD-ADNI consortium showed worse global cognitive function in Vietnam War veterans with PTSD, but did not reveal the expected and hypothesized increase in Aβ burden when considering the entire cerebral cortex as a single volume of interest ([@bb0385]). We hypothesized that the earlier analysis of this data may have missed focal alterations in Aβ deposition in the subgroup of long-term PTSD survivors, and furthermore that spatial mapping of Aβ might distinguish the PTSD group from groups with TBI and cases of mixed TBI and PTSD (TBI_PTSD). To test these linked hypothesis, we undertook a voxel-based re-analysis of the DOD-ADNI data sets, and made a statistical comparison of the PTSD, TBI and TBI_PTSD group findings contrasted with demographically matched control material.

2. Materials and method {#s0010}
=======================

2.1. Study subjects {#s0015}
-------------------

Data used in the preparation of this article were obtained from the DOD-ADNI as part of ADNI database ([adni.loni.usc.edu](http://adni.loni.usc.edu){#ir0015}) which was launched in 2003 as a public-private partnership, led by Principal Investigator Michael W. Weiner, MD. The primary goal of ADNI has been to test whether serial MRI, PET, other biological markers, and clinical and neuropsychological assessment can be combined to measure the mild cognitive impairment progression and early onset of AD. DOD-ADNI aimed at investigating the effect of TBI and PTSD on brain function and structure, and identifies the risk for progression to AD. For up-to-date information, see [www.adni-info.org](http://www.adni-info.org){#ir0020}.

Ethical approval to use the de-identified data was also obtained from the Human Research Ethics Committee of the University of Queensland, Australia (IRB number \#2017000630). Data were collected as part of a multicenter trial run by the DOD-ADNI initiative. In addition, as part of DOD-ADNI, all subjects signed an informed consent form including all the experimental procedures.

A total of 190 male Vietnam War veterans (age = 74.8 ± 6.2 years) were recruited by the DOD-ADNI study. After a rigorous quality control of the PET imaging data for motion, attenuation and other image artifacts, there remained 166 subjects (age 73.7 ± 6.2 years). These individuals belonged to one of four clinical groups: healthy controls without psychiatric or neurological illness (n = 57 subjects), PTSD without TBI (PTSD; n = 57 subjects), PTSD with TBI (TBI_PTSD; n = 29 subjects), and moderate/severe TBI without PTSD (TBI; n = 21 subjects), as shown in [Fig. 1](#f0005){ref-type="fig"}. We excluded from our study a total of 17 male veterans of non-Caucasian ethnicity, as shown in [Fig. 1](#f0005){ref-type="fig"}. Here, our intention was to eliminate confounds due to possible ethnicity-related differences in brain volume ([@bb0145]) and grey matter integrity ([@bb0235]), as shown in [Fig. 1](#f0005){ref-type="fig"}. All subjects had served during the Vietnam War with or without documented history of moderate-severe non-penetrating TBI related to military service, and with/without evidence of PTSD identified using the Structured Diagnostic Interview for DSM-V & Clinician Administered PTSD Scale (CAPS) with a cut-off score of 30 (refer to [Fig. 1](#f0005){ref-type="fig"}. for further details on the study population).Fig. 1Final groups and clinically classified subjects. Subjects were classified into four different groups including healthy controls, traumatic brain injury (TBI), post-traumatic stress disorder (PTSD), and TBI subjects with PTSD (TBI_PTSD).Fig. 1

2.2. Study design {#s0020}
-----------------

The study is a multimodality non-randomized natural history non-intervention study. DOD-ADNI recruited Vietnam War Veterans, identified from the Veteran Affairs Compensation and Pension records, to undergo a multitude of assessments including magnetic resonance imaging (MRI), amyloid PET using \[^18^F\]-AV45 (Forbetapir), cognitive testing, cerebral spinal fluid biomarkers of tau, phosphorylated-tau, Aβ, and blood sampling for analysis of genetic factors associated with a history of TBI or ongoing PTSD.

2.3. Neuropsychological assessment {#s0025}
----------------------------------

All participants underwent a battery of cognitive and neuropsychological assessments including Montreal Cognitive Assessment (MoCA) ([@bb0275]), Everyday Cognition (ECog) ([@bb0080]), Mini-Mental State Exam (MMSE) ([@bb0095]), Alzheimer\'s Disease Assessment Scale-Cognitive (ADAS-Cog) ([@bb0345]), American National Adult Reading Test (AMEreading) ([@bb0350]), Clinical Dementia Rating (CDR) ([@bb0260]), Functional Assessment Questionnaire ([@bb0150]), Combat Exposure Scale (CES), and Geriatric Depression Scale (GDtotal).

2.4. Cerebrospinal fluid (CSF) sample collection and analysis {#s0030}
-------------------------------------------------------------

CSF samples were collected through lumbar puncture and were analyzed with established ADNI methods ([@bb0005]) to measure levels of Aβ42, total tau, and phosphorylated tau at threonine 181 (p-tau~181~) using the validated Luminex xMAP multiplex immunoassay platform.

2.5. MRI and PET imaging {#s0035}
------------------------

### 2.5.1. MRI acquisition {#s0040}

All procedures were standardized across all sites for the conduct and acquisition of the data using qualified ADNI systems. T1-weighted anatomical image was acquired with a Spoiled Gradient Recalled Echo sequence (TE/TI/FA/BW1 = Min/400/11/31.25, sagittal plane, matrix size 256 × 256 × 200 and resolution 1 × 1 × 1.2 mm).

### 2.5.2. PET acquisition {#s0045}

Amyloid PET images were acquired using \[^18^F\]-AV45, a radiopharmaceutical that binds to amyloid plaques. A dose of 370 MBq (10 mCi ± 10%) bolus injection of \[^18^F\]-AV45 was administered to each subject followed by resting-uptake phase of 50 min, whereupon subjects were positioned within the tomograph for acquisition of four emission frames of 5 min each. PET images were 3D reconstructed using Iterative (fully 3D Iteration; four iterations; 20 subsets) with a grid of 128 × 128, FOV: 256 × 256 mm, slice thickness: 3.27 mm.

2.6. Image preprocessing and analysis {#s0050}
-------------------------------------

Data pre-processing and analysis were performed using FMRIB\'s Software Library ([@bb0160]) (FSL 5.0.9, Analysis Group, FMRIB, Oxford, UK, 2012) and Freesurfer ([@bb0090]) (Martinos Center for Biomedical Imaging, Laboratory for Computational Neuroimaging, Boston, United States).

### 2.6.1. MRI image processing {#s0055}

MR images were reoriented to match with the Montreal Neurological Institute (MNI) structural template ([@bb0105]) and MRI image were segmented using the *RECON-ALL* function from Freesurfer. The cerebellum of each subject was segmented for the preprocessing of the PET data. Structural data were then resampled to 1.5 mm isotropic resolution and co-registered to the MNI-152 template using nonlinear co-registration tool (FNIRT) ([@bb0025]).

### 2.6.2. PET pre-processing {#s0060}

The four emission frames were co-registered to each other to correct for head motion, and standard uptake value (SUV) was calculated voxel wise. The SUV images were reoriented to the FSL orientation and resampled to 1.5 × 1.5 × 1.5 mm^3^ to match with the MNI template\'s resolution. The SUV maps were coregistered to each subject\'s T1-weighted image using a linear co-registration tool (Flirt) ([@bb0155]) to match the subject\'s SUV map with the individual structural MRI image. To compute the referenced SUV (SUVR) maps, we followed the conventional practice in in scaling the entire brain signal intensity to the mean activity in the individual cerebellum (WH + GM), which was segmented on the MRI. This is a standard approach for transforming SUV maps to normalized SUVR maps for this PET tracer ([@bb0335]; [@bb0385]). In particular, we co-registered the SUV maps of each individual to the corresponding segmented T1 structural MRI data, and then extracted the cerebellum SUV value, which was used to calculate parametric SUVR maps of each individual.

The SUVR maps were co-registered to the MNI template using both the transformation matrix and warp files calculated for the T1-MRI registration to the MNI template. The registered SUVR maps were smoothed using a Gaussian filter with a common isotropic resolution of 6 mm and amyloid positivity was defined according to the threshold of SUVR \>1.1 ([@bb0210]).

2.7. Statistical analysis {#s0065}
-------------------------

Neuropsychological data were analyzed using RStudio 3.3.3. Since non-normality was present in the data, we performed nonparametric tests using Kruskal-Wallis tests to examine group differences, followed by performance of pairwise comparisons using Conover-Iman tests and Spearman\'s rho to examine the correlations between measurements. Statistical significance was set at α = 0.05. Correlations between CSF β-amyloid and tau levels, and SUVR of the parietal, temporal, frontal and cingulate cortices were calculated for each group using Spearman\'s rho correlation test.

PET SUVR maps were used to generate group\'s average maps using the one sample *t*-test with FSL-randomize ([@bb0390]). To contrast the amyloid accumulation in clinical groups versus the control group, we used an unpaired 2-sample *t*-test to generate voxel-based difference maps using FSL-randomize nonparametric permutation tests with 1000 permutations. Results were corrected using cluster-based correction through threshold-free cluster enhancement (*p* \< 0.05, cluster volume \> 40 voxels).

To investigate the group differences in brain regions by VOI analysis, individuals\' SUVR values were extracted from a set of templates including frontal, cingulate, parietal, temporal cortices, anterior cingulate cortex, middle temporal gyrus, inferior parietal lobule, medial frontal gyrus and precuneus, all defined in the individual structure MRI data. The group VOI data were analyzed using unpaired *t*-test to identify regions with significant differences between groups, with Bonferroni correction (*p* \< 0.05). Correlations between CSF amyloid and tau, and SUVR of the parietal, temporal, frontal and cingulate cortices were calculated for each group using Pearson\'s r-correlation test (*p* \< 0.05).

3. Results {#s0070}
==========

3.1. Clinical outcome and TBI and/or PTSD groups {#s0075}
------------------------------------------------

The mean current-CAPS scores were significantly higher in the PTSD group in contrast to TBI_PTSD (*p* \< 0.0001), and both PTSD/TBI_PTSD had higher mean scores than the control (*p* \< 0.0001) and TBI group (*p* \< 0.00001). The mean CDRGLOBAL score was higher in PTSD compared to controls (*p* \< 0.00001) and TBI_PTSD (*p* \< 0.001), suggesting that cognitive deficits were more pronounced in both PTSD groups than in the TBI alone or healthy control groups. Mean CES score was significantly higher in the PTSD/TBI_PTSD groups compared to controls (*p* \< 0.00001), but only the PTSD group had significantly higher CES scores than did the TBI group (*p* \< 0.01). The mean GDtotal score was higher in PTSD/TBI_PTSD groups compared to controls (*p* \< 0.0001), and higher in the PTSD compared to the TBI group (*p* \< 0.0001). The mean total ECog scores indicated significantly worse cognition in the PTSD/TBI_PTSD groups compared to the control (*p* \< 0.0001, *p* \< 0.001) and TBI groups (*p* \< 0.01, *p* \< 0.01). Within ECog scores, the PTSD/TBI_PTSD groups showed worse memory ability in contrast to healthy controls (*p* \< 0.0001, *p* \< 0.001), while the PTSD group showed worse visuospatial ability (*p* \< 0.00001); planning and divided attention abilities were significantly worse in both groups compared to controls (*p* \< 0.0001). MMSE and MoCA scores showed no significant differences between groups (*p* \> 0.05). The AMEreading scores showed that the PTSD group had significantly more errors compared to controls (*p* \< 0.001). Full scale IQ test score was significantly lower in the PTSD group compared to healthy controls (*p* \< 0.01); see [Table 1](#t0005){ref-type="table"}, [Fig. 2](#f0010){ref-type="fig"}.Table 1Demographics and Neuropsychological performance by groups.Table 1HealthyTBITBI_PTSDPTSDMean (STD)Mean (STD)Mean (STD)Mean (STD)Number of subjects57213157Number of CSF279623Age70.9 (6.01)67.9 (4.4)68.7 (3.1)67.8 (3.7)Males (%)100100100100ADAS-Cog10.8 (4.58)9.4 (3.6)11 (5.2)12.8 (3.9)CAPS Current2.22 (4.14)7.36 (6.21)39.08 (11.96)56.64 (11.48)CDR0.05 (0.2)0.33 (0.56)0.47 (0.24)0.21 (0.27)CES10.89 (10.2)17 (10.35)24.4 (10.12)24.13 (8.88)GDtotal0.712 (0.91)1.41 (1.91)2.96 (2.6)4 (2.82)ECog memory13.31 (5.25)13.06 (5.47)17.22 (5.77)16.06 (5.67)ECog language13.12 (5.86)12.53 (5.61)15.93 (6.43)17.11 (7.25)ECog visspat7.68 (1.24)8.82 (3.52)9.48 (3.98)9.89 (3.72)ECog plan5.88 (1.5)7.06 (3.54)7.96 (3.19)7.7 (2.76)ECog divatt5.66 (2.09)6.53 (2.83)8.22 (3.75)7.85 (3.29)ECog total54.61 (15.08)57.82 (22.97)70.74 (23.72)69.74 (23.35)MMSE28.75 (1.28)28.94 (1.03)28.22 (1.53)28.09 (1.66)MOCA24.86 (2.76)25.18 (3.36)23.41 (2.89)23.49 (3.84)AMEreading12.73 (8.11)14.41 (8.43)14.22 (10.77)18.55 (11.27)FSIQ117.2 (6.65)115.7 (6.880)115.9 (8.93)112.4 (9.28)[^2]Fig. 2Charts showing the Neurophysiological and clinical outcomes differences. Significant differences were identified with *p* \< 0.01. CAPS, Clinician-Administered PTSD Scale; CES, Center for Epidemiologic Studies Depression Scale; CDR, Clinical Dementia Rating; ECOGtotal, total score for Everyday cognition; GDtotal, Geriatric Depression Scale; FSIQ, Full Scale Intelligence Quotient; TBI, traumatic brain injury; PTSD, post-traumatic stress disorder; TBI_PTSD, TBI subjects who developed PTSD.Fig. 2

3.2. Amyloid deposition in TBI and/or PTSD groups {#s0080}
-------------------------------------------------

[Fig. 3](#f0015){ref-type="fig"}. illustrates the p-statistic maps of each group mean SUVR maps, revealing regions with significantly elevated uptake (SUVR \>1.1) for each of the four study groups. There were sparse cortical regions of higher tracer uptake in the healthy control groups, but these regions were more extensive in the clinical groups. Interestingly, the TBI_PTSD group showed increased mean SUVR in the white matter while PTSD showed the highest zones of cortical SUVR relative to controls, see [Fig. 3](#f0015){ref-type="fig"}.Fig. 3\[^18^F\]-AV45 SUVR average maps for each group showing region with amyloid positive uptake in the brain for different groups. Healthy controls showed the lowest uptake (A), while clinical groups showed more uptake in TBI, with higher in TBI_PTSD and the highest SUVR values in PTSD.Fig. 3

3.3. Group differences in amyloid deposition between TBI and/or PTSD groups {#s0085}
---------------------------------------------------------------------------

Significant differences in \[^18^F\]-AV45 SUVR in the three clinical groups compared to the controls are represented in [Fig. 4](#f0020){ref-type="fig"}. TBI subjects had significantly higher \[^18^F\]-AV45 SUVR in the cerebellar tonsil (1.32 ± 0.21 versus 1.12 ± 0.25; *p* = 0.038) and precuneus (1.25 ± 0.21 versus 0.87 ± 0.20; *p* = 0.029) compared to controls, while SUVR was lower in ventrolateral prefrontal cortex (1.12 ± 0.2 versus1.2 ± 0.19; *p* = 0.041); see [Fig. 4](#f0020){ref-type="fig"}A and [Fig 5](#f0025){ref-type="fig"}.Fig. 4Groups comparisons of \[^18^F\]-AV45 SUVR between clinical groups and healthy group. A. TBI vs. healthy controls, B. TBI_PTSD vs. healthy control, and C. PTSD vs. healthy control. Red-yellow means higher means higher amyloid in clinical groups while blue-green means higher amyloid in healthy controls. Difference maps were calculated using unpaired *t*-test amyloid in clinical groups and blue and green test and results were corrected using cluster-based correction (*p* \< 0.05, Z \> 2.3, cluster \>40 voxels). (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)Fig. 4Fig. 5Shows the referenced standard uptake values (SUVR) for the five brain lobes. It shows significant SUVR differences between groups in the five VOIs, i.e. frontal, cingulate, parietal, occipital and temporal lobes.Fig. 5

The TBI_PTSD group showed increased \[^18^F\]-AV45 SUVR relative to controls, which was more localized to the white matter (1.6 ± 0.31 versus 1.32 ± 0.34; *p* = 0.027) especially in the corpus callosum (1.84 ± 0.5 versus 1.52 ± 0.5; *p* = 0.009), cingulate cortex (1.52 ± 0.36 versus 1.31 ± 0.4; *p* = 0.01), the middle temporal gyrus (1.25 ± 0.185 versus 1.12 ± 0.26; *p* = 0.048), while uptake was significantly lower comparted to controls in the middle frontal gyrus (1.21 ± 0.35 versus 1.48 ± 0.21; *p* = 0.032), superior temporal gyrus (1.5 ± 0.28 versus 1.7 ± 0.19; *p* = 0.028), and inferior parietal cortex (1.2 ± 0.21 versus 1.42 ± 0.34; *p* = 0.031); see [Fig. 4](#f0020){ref-type="fig"}B and [Fig 5](#f0025){ref-type="fig"}.

PTSD group had significantly higher \[^18^F\]-AV45 SUVR in various cortical areas including the prefrontal cortex (1.43 ± 0.2 versus 0.93 ± 0.41; *p* = 0.041), orbital gyrus (1.52 ± 0.29 versus 1.18 ± 0.21; *p* = 0.034), superior, middle and inferior temporal gyrus (1.2 ± 0.23 versus 1.21 ± 0.24; *p* = 0.032), hippocampus (1.56 ± 0.3 versus 1.3 ± 0.41; *p* = 0.031), middle and inferior occipital gyrus (1.52 ± 0.18 versus 1.3 ± 0.21; *p* = 0.021), posterior cingulate gyrus (1.2 ± 0.12 versus 0.92 ± 0.41; *p* = 0.05), and supplementary motor area (1.52 ± 0.32 versus 1.3 ± 0.31; *p* = 0.04), all compared to controls; see [Fig. 4](#f0020){ref-type="fig"}C and [Fig 5](#f0025){ref-type="fig"}.

3.4. Correlation between amyloid tracer uptake in brain and amyloid and tau levels in CSF {#s0090}
-----------------------------------------------------------------------------------------

[Fig. 6](#f0030){ref-type="fig"} shows the correlations between \[^18^F\]-AV45 SUVR in four ROIs with the CSF amyloid concentrations. Healthy controls showed negative correlation in frontal (r2 = 0.15; *p* = 0.046), parietal (r2 = 0.152; *p* = 0.045), and cingulate (r2 = 0.16; *p* = 0.036) cortices. Interestingly we observed significant negative correlations in the TBI-alone group in frontal (r2 = 0.22; *p* = 0.03), parietal (r2 = 0.27; *p* = 0.036), cingulate (r2 = 0.25; *p* = 0.04), and temporal cortex (r2 = 0.3; *p* = 0.033), and also in the TBI_PTSD group for frontal (r2 = 0.51; *p* = 0.026), parietal (r2 = 0.69; *p* = 0.03), cingulate (r2 = 0.36; *p* = 0.02), and temporal cortex (r2 = 0.13; *p* = 0.04); see [Fig. 6](#f0030){ref-type="fig"} and [Table 2](#t0010){ref-type="table"}.Table 2Correlations between amyloid in the brain and cerebrospinal fluid concentrations of amyloid and tau.Table 2HealthyTBITBI_PTSDPTSDR^2^ (*p*)R^2^ (*p*)R^2^ (*p*)R^2^ (*p*)CSF AmyloidFrontal0.15 (*p* = 0.046)0.22 (*p* = 0.03)0.51 (*p* = 0.026)0.05 (*p* = 0.85)Parietal0.152 (*p* = 0.046)0.27 (*p* = 0.036)0.69 (*p* = 0.03)0 (*p* = 0.3)Cingulate0.16 (*p* = 0.036)0.25 (*p* = 0.04)0.36 (*p* = 0.02)0.09 (*p* = 0.67)Temporal0.02 (*p* = 0.8)0.3 (*p* = 0.033)0.13 (*p* = 0.04)0.01(*p* = 0.7)Frontal0.16 (*p* = 0.27)0.36 (*p* = 0.043)0 (*p* = 0.9)0.03 (*p* = 0.7)CSF TauParietal0.08 (*p* = 0.12)0.33 (*p* = 0.029)0 (*p* = 0.86)0 (*p* = 0.2)Cingulate0.09 (*p* = 0.3)0.3 (*p* = 0.036)0.09 (*p* = 0.6)0.12 (*p* = 0.4)Temporal0.24 (*p* = 0.01)0.3 (*p* = 0.01)0.14 (*p* = 0.34)0 (*p* = 0.3)

[Fig. 7](#f0035){ref-type="fig"} shows the correlations between individual \[^18^F\]-AV45 SUVR in four cortical ROIs with CSF tau-protein concentrations. Significant positive correlations were observed in the healthy control group within frontal (r2 = 0.16; *p* = 0.027) and temporal cortex (r2 = 0.24; *p* = 0.01). Significant positive correlations were observed in the TBI group within frontal (r2 = 0.36; *p* = 0.043), cingulate (r2 = 0.3; *p* = 0.036), parietal (r2 = 0.33; *p* = 0.029), and temporal cortex (r2 = 0.3; *p* = 0.01). There were no such significant correlations in the PTSD or TBI_PTSD groups; see [Fig. 7](#f0035){ref-type="fig"} and [Table 2](#t0010){ref-type="table"}.

4. Discussion {#s0095}
=============

We used \[^18^F\]-AV45 PET imaging to investigate Aβ deposition in brain of Vietnam War veterans, seeking in particular to identify effects of PTSD alone or in association with TBI on this neuropathological marker. Earlier analysis of the data, considered the whole cerebral cortex as single ROI, had failed to reveal evidence for amyloidosis in brain of the veterans with PTSD and/or TBI ([@bb0385]), but we felt that a voxel-wise statistical comparison might reveal regional patterns of amyloid accumulation not evident in that study. Indeed, we found notable accumulations of amyloid in the frontal, occipital and temporal lobes of PTSD sufferers with significant cognitive dysfunction, and in the white matter of TBI_PTSD group. Furthermore, we found correlation between amyloid PET results and CSF markers of neuropathology in the TBI and TBI_PTSD groups.

4.1. Neurocognition as a marker of progression to AD {#s0100}
----------------------------------------------------

A broad battery of neuropsychological tests had been collected to assess cognitive function in these Vietnam war veterans. The PTSD patients exhibited the worst cognitive performance on all assessments, followed by TBI_PTSD subjects, whereas cognitive scores in the TBI and control groups did not differ ([Fig. 2](#f0010){ref-type="fig"}).

TBI is a risk factor for PTSD ([@bb0400]), and both bring high risk for developing dementia later in life ([@bb0010]; [@bb0315]). Indeed, 63% of our TBI participants had developed PTSD with a life CAPS score \> 40 and current CAPS score \> 30. This is consistent with previous findings that veterans with deployment-related TBI had more severe post-deployment PTSD symptoms ([@bb0410]), and that most TBI patients also suffer from PTSD ([@bb0410]). The causal link between TBI and PTSD may relate to the physical and cognitive impairment arising from the TBI, both of which increase PTSD prevalence ([@bb0200]; [@bb0400]). Alternately, emotional trauma arising in proportion to severity of the TBI may be the driver for developing PTSD ([@bb0410]).

We observed reduced cognitive function in both the PTSD and TBI_PTSD groups for all sub-categories of the ECog scale. While prior studies have not used ECog to investigate cognitive performance in relation to daily life of PTSD patients, several studies report lower cognitive function among PTSD patients ([@bb0065]; [@bb0110]; [@bb0320]). The present changes suggest that altered brain structure or function following TBI may be associated with a risk for developing PTSD, neurodegenerative disease, or cognitive impairment.

In a recent study, Li et al. showed that age at the time of TBI influences ECog scores, with significantly higher ECog scores in all domains among patients experiencing their TBI during childhood ([@bb0225]). We suppose that TBI in young adulthood may likewise have propagated to more severe cognitive effects in the present group of veterans. The mean GDtotal score was higher in PTSD and TBI_PTSD groups compared to TBI alone and control groups, consistent with the previous report ([@bb0245]), which showed that 30% percent of PTSD patients had depression symptoms or depressive disorders 40 years after their Vietnam war service. The low incidence of behavioral and substance abuse disorders in our PTSD patients matches the findings of a previous study, where incidence of illicit drug use declined from 30% in 1972 to only 8% in 1996 ([@bb0035]).

4.2. Amyloid PET findings in the three clinical groups {#s0105}
------------------------------------------------------

TBI is now understood to provoke an acute increase of amyloid precursor protein (APP), the source for amyloid plaque formation, in response to axonal injury ([@bb0120]). Diffusion tensor imaging (DTI) consistently shows white matter changes due to axonal injury and tract degradation post-TBI ([@bb0205]). The present TBI group showed clusters of increased Aβ deposition mainly in the cerebellum and precuneus regions ([Fig. 4](#f0020){ref-type="fig"}), rather matching the pattern of increased \[^11^C\]-PiB binding reported in TBI patients scanned 1--17 years after injury ([@bb0335]). Others reported Aβ plaque evident to PET and histopathology examination performed directly after the TBI ([@bb0135]; [@bb0300]), and increased \[^11^C\]-PiB binding in cortex but not white matter of TBI patients scanned within one year of injury ([@bb0125]). However, presumed short term increases in plaque density were not evident to histopathological examination at some three years after the injury, despite an ongoing elevation of APP in the white matter ([@bb0050]). This implies that transient Aβ plaques can be substantially cleared in the years after TBI. In a post mortem study of long term TBI survivors, approximately one third had increased Aβ plaques, leading the authors to conclude that this subset of TBI survivors were at increased risk for developing AD ([@bb0170]). We suppose that the large variance of \[^18^F\]-AV45 SUVR in our TBI group of only 18 subjects may conceal some individuals with more pronounced amyloid levels.

The TBI_PTSD group showed increased \[^18^F\]-AV45 SUVR throughout the white matter, most clearly evident in the corpus callosum ([Fig. 4](#f0020){ref-type="fig"}B). Indeed, amyloid PET tracers characteristically label the white matter, irrespective of amyloid content ([@bb0045]), although other studies reported a subtle increase in \[^18^F\]-AV45 SUVR in white matter of AD patients compared to healthy controls, ([@bb0280]). Therefore we cautiously attribute the present findings in the TBI_PTSD group to indicate Aβ accumulation in white matter. Indeed, there is concurrence of Aβ deposition and altered DTI in white matter of humans with TBI ([@bb0040]), and, a DTI study reported that white matter was more compromised in TBI_PTSD patients than in those with TBI alone ([@bb0220]). Although not directly comparable to studies of recent injuries, we suppose that concurrent PTSD may have interfered with the recovery of axonal injury upon TBI in these veterans. In addition, we speculate that the history of TBI 40 years earlier initiated an Aβ pathology similar to that of AD, although it remains to be seen if this TBI cohort will progress to AD. To determine if the PET tracer used in this study could accurately predict the presence of β-amyloid in the brain at autopsy, we looked at the literature and found it does ([@bb0060]; [@bb0140]). In the study performed by Clark et al., 28 of a series of 29 AD patients who underwent Florbetapir-PET one year antimortem showed concord between PET and histopathological findings for β-amyloid positivity or negativity ([@bb0060]). In addition, Ikonomovic et al. showed that 90% of PET assessments of AD patients accurately reflected the amyloid plaque burden revealed from postmortem histology ([@bb0140]).

Veterans with PTSD have a two-fold increased risk for developing AD ([@bb0405]), but few studies have investigated the presence of Aβ in human PTSD. In animal models of PTSD entailing chronically elevated stress, the formation rate of amyloid plaques increased ([@bb0075]; [@bb0180]; [@bb0310]). Amyloid plaque deposition in AD has been a long-standing topic. Several imaging studies have demonstrated that Aβ feature of the AD brain; Johnson et al compared 45 AD patients in contrast to 79 healthy controls and showed that the AD group showed higher \[18F\]-AV45 uptake in the precuneus, frontal, temporal, parietal, and anterior and posterior cingulate cortices ([@bb0175]), with same pattern shown by Scott et al. ([@bb0335]), and supported by review reports ([@bb0055]; [@bb0270]; [@bb0375]). Interestingly, it has been shown that a history of PTSD symptoms increases the risk for developing AD ([@bb0295]; [@bb0405]b). Our results reflect similar findings where increased levels of Aβ are seen frontal, temporal, parietal, and anterior and posterior cingulate cortices in the brain of PTSD subjects that overlap with amyloid increase correspondent to AD (see [Table 3](#t0015){ref-type="table"}). This may suggest that amyloid could be a possible link between PTSD and AD supported by the overlapping etiologies for PTSD and AD. One possible cause for amyloid presence could be the stress-related changes in the hypothalamic--pituitary--adrenal (HPA) axis ([@bb0265]). Indeed, PTSD and AD are both characterized by volumetric loss in the hippocampus in association with cognitive decline ([@bb0180]b; [@bb0365]). The hippocampus is a particularly plastic and vulnerable region of the brain ([@bb0255]). Several MRI studies of PTSD patients have shown decreased volumes of hippocampus ([@bb0230]; [@bb0330]; [@bb0305]), anterior cingulate cortex ([@bb0330]; [@bb0340]), and prefrontal structures ([@bb0395]). Smaller hippocampal volumes have been repeatedly associated with development ([@bb0100]) and persistence ([@bb0305]) of PTSD symptoms. In contrast, some studies showed no volumetric increases in hippocampus even after full recovery from PTSD symptoms ([@bb0230]; [@bb0305]). Thus, the causal relation between PTSD and volumetric changes in PTSD patients remains uncertain. In addition, environmental and genetic factors can contribute importantly to the risk of developing PTSD ([@bb0100]; [@bb0215]). In support of a HPA contribution to neurodegenerative disease progression, corticosteroid levels are elevated in early AD patients ([@bb0070]). In this work, we investigated effects of PTSD decades following the diagnosis, and establish a tentative link between PTSD and β-amyloid accumulation in the brain. However, diverse factors and mechanisms may have had a direct impact on our β-amyloid findings; PTSD and AD are both highly associated with increased neuro-inflammatory mediators, including cytokines, chemokines, and other neurotoxic mediators such as tryptase, histamine, IL-1β, TNF-α, IL-6, CCL2, IL-8, ROS, CRH, and MMPs, any of which might contribute to neurodegeneration ([@bb0185]) and β-amyloid accumulation. Again, the cross-sectional design cannot establish the causal relationship between longer duration of PTSD and increased β-amyloid burden.Table 3Regions with increased β-amyloid with similar spatial distribution of β-amyloid both in TBI, PTSD and AD.Table 3TBI ([@bb0335])PTSDAD ([@bb0335])CerebellumyesNot reportedLess than TBICingulateNot reportedReportedReportedPre-frontal CortexNot reportedReportedReportedMedial prefrontal cortexNot reportedReportedReportedTemporal CortexNot reportedReportedReportedParietal cortexNot reportedReportedReportedPrecuneusReportedNot reportedReportedOccipitalNot ReportedReportedNot reportedThis table reports present results and findings of [@bb0335].

4.3. Correlation between SUVR in the brain and CSF amyloid and tau {#s0110}
------------------------------------------------------------------

The CSF concentration of Aβ is reduced while tau levels are elevated in AD patients ([@bb0030]; [@bb0355]), and these typical CSF findings correlate with cerebral amyloid burden in PET ([@bb0250]; [@bb0335]). Although we found no significant correlations between our CSF markers and regional \[^18^F\]-AV45 SUVR in the PTSD and control groups, amyloid PET results in the TBI and TBI_PTSD groups showed negative correlations with CSF Aβ concentration and positive correlations with CSF tau concentration. Thus, the TBI findings resemble those reported earlier for AD patients ([@bb0030]; [@bb0355]).

In severe TBI patients, increased CSF tau protein and decreased CSF Aβ levels were predictive for poor clinical outcomes ([@bb0195]; [@bb0285]; [@bb0290]; [@bb0360]), whereas [@bb0285] reported CSF p-tau increase in boxers to correlate positively with the duration after TBI. In addition, the tau concentration in brain interstitial fluid was more increased in cases of focal cortical injury than in patients with axonal injury ([@bb0240]; [@bb0360]). As such, present results are consistent with a persistence of elevated tau secretion into CSF persisting decades after TBI alone or in conjunction with PTSD.

Present correlations between PET-SUVR with CSF markers in the TBI and TBI_PTSD groups may suggest link between the brain β-amyloid and CSF amyloid accumulation, which resembles the hallmark pathology of AD, and may thus suggest an increased risk TBI and TBI_PTSD patients to develop AD later in life. In addition, a similar trend of negative correlations was observed in aged healthy controls, as shown in [Fig. 6](#f0030){ref-type="fig"}. However, the mechanisms causing the increased β-amyloid in the brain both in the TBI and PTSD groups could differ. As shown from the results, we observed increased β-amyloid in the TBI only group, which localized to the cerebellum and precuneus. However, the group with TBI and PTSD showed a substantial increase of β-amyloid burden in the white matter, whereas the PTSD alone group showed main increases of β-amyloid at the frontal, occipital and temporal cortices. These differences between the three clinical groups in the spatial distribution and maximal SUVR may explain the differing relationships between β-amyloid to PET and CSF concentrations of tau and β-amyloid in all three groups.Fig. 6Shows the correlation between SUVR in different lobes of the brain and the amyloid in cerebrospinal fluid. There were significant negative correlations observed in both TBI and TBI_PTSD groups.Fig. 6Fig. 7Shows the correlation between SUVR in different lobes of the brain and the tau in cerebrospinal fluid. Significant positive correlations observed in all regions for TBI and only in frontal lobe for TBI_PTSD.Fig. 7

This study is subject to limitations arising in relation to preinjury functioning ([@bb0020]) and socioeconomic status attained in civilian life. ([@bb0130]). Notwithstanding, our voxel wise reanalysis of the DOD-ADNI data reveals focally increased Aβ accumulation in brain of PTSD and TBI patients, suggesting a partial overlap with AD pathology, with increased Aβ in the occipital and temporal cortex in PTSD patients, whereas increases are restricted to the white matter in the TBI_PTSD cases. Irrespective of anatomic location, the increased Aβ burden was associated with lower cognitive performance in these Vietnam war veterans. The limited number of CSF samples available is yet another limitation in making conclusive statements about observed correlations with brain amyloid SUVR values. Despite the limited number of subjects in the TBI and TBI_PTSD groups, we were nonetheless able to see a significant correlation between PET and CSF concentrations of β-amyloid and Tau in both clinical TBI groups. Further analysis with larger samples size will be required to confirm the patterns. The cross-sectional, non-randomized study design also adds to these limitations and caution should be taken when making inferences on the correlations between CSF and brain β-amyloid.

5. Conclusion {#s0115}
=============

In a voxel-wise comparison of the \[^18^F\]-AV45 PET data, we detected focally increased Aβ in cortex of the PTSD group and in white matter of the TBI plus PTSD group. Thus, we see the first evidence of increased Aβ in long-term PTSD sufferers, suggesting that cortical pathology contributes to their cognitive deficits. Our voxel-wise analysis of \[^18^F\]-AV45 revealed patterns of increased Aβ uptake that had not been discernible when examining the cerebral cortex as a single volume of interest.
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[^1]: Data used in preparation of this article were obtained from the Alzheimer\'s Disease Neuroimaging Initiative (ADNI) database ([adni.loni.usc.edu](http://adni.loni.usc.edu){#ir0005}). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. A complete listing of ADNI investigators can be found at: <http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf>.

[^2]: MoCA, Montreal Cognitive Assessment; ECog, Everyday Cognition; CAPS, Clinician-Administered PTSD Scale; MMSE, Mini-Mental State Exam; ADAS-COG, Alzheimer\'s Disease Assessment Scale-Cognitive; CDR, Clinical Dementia Rating; GDtotal, Geriatric Depression Scale; AMEreading, American Reading test; FSIQ, Full Scale Intelligence Quotient; CES, Center for Epidemiologic Studies Depression Scale.
